[HTML][HTML] Corticosteroid Therapy in Immunoglobulin A Nephropathy: A Friend or Foe?

D Kim, MG Wong - Kidney and Blood Pressure Research, 2023 - karger.com
Background: The administration of corticosteroids in addition to supportive care to delay
progressive immunoglobulin A nephropathy (IgAN), the most common primary …

[HTML][HTML] A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy

L Tan, Y Tang, G Pei, Z Zhong, J Tan, L Zhou, D Wen… - Scientific Reports, 2021 - nature.com
It was reported that histopathologic lesions are risk factors for the progression of IgA
Nephropathy (IgAN). The aim of this study was to investigate the relationships between …

New insights into the immunity and podocyte in glomerular health and disease: from pathogenesis to therapy in proteinuric kidney disease

PXM Rangel, A Priyadarshini… - Integrative Medicine in …, 2021 - journals.lww.com
Evidence has been furnished that immune cells, and immune-podocytes interactions have
increasingly become the focus of proteinuric kidney diseases, which affect millions of …

[HTML][HTML] Challenges in IgA nephropathy management: an era of complement inhibition

V Tesař, J Radhakrishnan, V Charu, J Barratt - Kidney International Reports, 2023 - Elsevier
IgA nephropathy (IgAN) is the most common glomerular disease worldwide, with an
estimated annual incidence of 25 per million adults. Despite optimized supportive care …

C4d in native glomerular diseases

P Chandra - American journal of nephrology, 2019 - karger.com
Complement activation occurs in many glomerular diseases, the exact pathway (s) of
activation has been studied in detail in some diseases but not in all. C4d is generated by the …

[HTML][HTML] An Update on Current Therapeutic Options in IgA Nephropathy

RS Lim, SC Yeo, J Barratt, DV Rizk - Journal of Clinical Medicine, 2024 - mdpi.com
Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular
disease worldwide. Outcomes are poor with high rates of progressive chronic kidney …

[HTML][HTML] Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis

H Suzuki, Z Moldoveanu, BA Julian, RJ Wyatt… - Kidney international …, 2019 - Elsevier
Introduction Patients with IgA nephropathy (IgAN) have elevated serum levels of galactose-
deficient IgA1 (Gd-IgA1) that are bound by Gd-IgA1–specific autoantibodies in pathogenic …

Increased renal expression of complement components in patients with liver diseases: nonalcoholic steatohepatitis, alcohol-associated, viral hepatitis, and alcohol …

KL Frost, JL Jilek, AD Thompson, RR Klein… - Toxicological …, 2022 - academic.oup.com
Inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH), alcohol-
associated liver disease (ALD), hepatitis C virus (HCV), and ALD/HCV, account for nearly 2 …

Immunoglobulin A glycosylation and its role in disease

AL Hansen, C Reily, J Novak, MB Renfrow - Antibody Glycosylation, 2021 - Springer
Human IgA is comprised of two subclasses, IgA1 and IgA2. Monomeric IgA (mIgA),
polymeric IgA (pIgA), and secretory IgA (SIgA) are the main molecular forms of IgA. The …

Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population

D Shi, Z Zhong, M Wang, L Cai, D Fu, Y Peng… - Journal of Human …, 2020 - nature.com
Genome-wide association studies (GWAS) had discovered several genetic risk loci for IgA
nephropathy (IgAN), where the susceptibility genes of CARD9 and HORMAD2 for IgAN were …